Clinical Trial Update: Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis [Phase 2]

View source ↗

Summary

Phase 2 long-term safety study of ASN002 in moderate to severe atopic dermatitis was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• ASN002

Snippet

Sponsor: Asana BioSciences | Conditions: Atopic Dermatitis | Phase 2 | Status: TERMINATED | Results posted: 2023-09-18